Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$5.31 ▼ -0.04
(-0.75%)
MKT CAP: $289.8M • VOL: 553.1K
52W L $5 52W H $17
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$4
MEDIAN
$6
MEAN
$6
HIGH
$7
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE EIKN TAPE
EIKN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $6.43 | $6.11 | 2025-02-14 | $4.83 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $6.69 | $6.27 | 2025-02-06 | $4.99 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $6.05 | $5.84 | 2025-01-29 | $5.10 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $5.42 | — | 2025-01-17 | $5.20 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $4.67 | $5.04 | 2025-01-09 | $4.73 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $6.32 | $5.52 | 2024-12-18 | $4.62 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $5.15 | $5.36 | 2024-12-04 | $4.94 | -4.3% | 48% | C |